



Wissenschaftl. Publikationen der Augenabteilung am Akh Linz

(Originalarbeiten)

2011

1. **An in-vivo Evaluation of Brilliant Blue G in Macular Surgery.** Höing A, Remy M, Dirisamer M, Priglinger S, Schönfeld CL, Kampik A, Haritoglou C. *Klin Monbl Augenheilkd.* 2011 Apr 8. [Epub ahead of print] IF: 0,470
2. **Quantification of Contrast Recognizability During Brilliant Blue G (BBG) and Indocyanine Green (ICG) Assisted Chromovitrectomy.** Henrich PB, Priglinger SG, Haritoglou C, Josifova T, Ferreira PR, Strauss RW, Flammer J, Cattin PC. *Invest Ophthalmol Vis Sci.* 2011 Mar 2. [Epub ahead of print] IF: 3,58
3. **Endothelial cell density after Descemetmembrane endothelial keratoplasty:1-4 year follow-up.** Parker J, Dirisamer M, Naveiras M, Ham L, van der Wees J, Melles G. *AJO* 2011, accepted for publication IF: 3,10
4. **Descemet membrane endothelial transfer (DMET): Free floating donor Descemet implantation as a potential alternative to 'keratoplasty'.** Dirisamer M, Ham L, Dapena I, Naveiras M, van Dijk K, van der Wees J, Melles G. *CORNEA* 2011 accepted for publication IF: 1,9
5. **Patterns of corneal endothelialization and corneal clearance after Descemet membrane endothelial keratoplasty for Fuchs endothelial dystrophy** Dirisamer M, Dapena I, Ham L, Naveiras M, van Dijk K, Oganis O, Frank L, van der Wees J, Melles G. *AJO* 2011 accepted for publication IF: 3,1
6. **Secondary 'Thin DSEK' after longterm graft failure in DLEK: A double transplanted.**Dirisamer M, Acis G, Dapena I, Ham L, Versteeg F, Melles G. *Cornea* 2011, accepted for publication IF: 1,9
7. **Efficacy of Descemet membrane endothelial keratoplasty (DMEK): Clinical outcome of 200 consecutive cases after a 'learning curve' of 25 cases.** Dirisamer M, Ham L, Dapena I, Moutsouris K, Droutsas K, van Dijk K, Frank L, van der Wees J, Oellerich S, Melles G. *Arch of Ophthalmol.* 2011, accepted for publication IF: 3,2
8. **Static Retinal Vessel Analysis in Acute Blood Pressure Increase.** Strauss RW, Lüdtko U, Kampik A, Neubauer AS. *Klin Monbl Augenheilkd.* 2011 Mar 25. [Epub ahead of print] German.

2010

9. **Anatomic Success of Scleral Buckling for Rhegmatogenous Retinal Detachment - A Retrospective Study of 524 Cases.** Haritoglou C, Brandlhuber U, Kampik A, Priglinger SG *Ophthalmologica*. 2010 Mar 23;224(5):312-318 IF: 1.093
10. **ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degenerations.** Kortvely E, Hauck SM, Duetsch G, Gloeckner CJ, Kremmer E, Alge-Priglinger CS, Deeg CA, Ueffing M. *Invest Ophthalmol Vis Sci*. 2010 Jan;51(1):79-88. Epub 2009 Aug IF: 3,6
11. **Negative regulation of RPE cell attachment by carbohydrate-dependent cell surface binding of galectin-3 and inhibition of the ERK-MAPK pathway.** Alge-Priglinger CS, André S, Schoeffl H, Kampik A, Strauss RW, Kernt M, Gabius HJ, Priglinger SG. *Biochimie*. 2010 Nov 20 IF: 3.489
12. **Ultrastructure and retinal imaging of internal limiting membrane: a clinicopathologic correlation of trypan blue stain in macular hole surgery.** Mackenzie SE, Gandorfer A, Rohleder M, Schumann R, Schlottmann PG, Bunce C, Xing W, Gregor Z, Charteris DG. *Retina*. 2010 Apr;30(4):655-61. IF: 3,5
13. **Amadeus II microkeratome: optimizing microkeratome settings for high flap accuracy using optical low coherence reflectometry.** Lackerbauer CA, Kollias A, Kreutzer TC, Ulbig M, Kampik A, Grueterich M. *Eur J Ophthalmol*. 2010 Jan-Feb;20(1):41-7. IF: 1,0
14. **Sorafenib prevents human retinal pigment epithelium cells from light-induced over-expression of VEGF, PDGF and PIGF.** Kernt M, Neubauer AS, Liegl RG, Hirneiss C, Alge CS, Wolf A, Ulbig MW, Kampik A. *Br J Ophthalmol*. 2010 Nov;94(11):1533-9. IF: 2,9
15. **Indocyanine green increases light-induced oxidative stress, senescence, and matrix metalloproteinases 1 and 3 in human RPE cells.** Kernt M, Hirneiss C, Wolf A, Liegl R, Rueping J, Neubauer A, Alge C, Ulbig M, Gandorfer A, Kampik A, Haritoglou C *Acta Ophthalmol*. 2010 Jul 29 IF: 2,1

2009

16. **Vital dyes for macular surgery: a comparative electron microscopy study of the internal limiting membrane.** Schumann RG, Gandorfer A, Priglinger SG, Kampik A, Haritoglou C. *Retina*. 2009; 29:669-76. IF: 3,478
17. **Macula-off retinal detachment--a matter of time?** Henrich PB, Priglinger S, Klaessen D, Kono-Kono JO, Maier M, Schötzau A, Meyer P, Josifova T, Schneider U, Flammer J, Haritoglou C. *Klin Monatsbl Augenheilkd*. 2009; 226:289-93. IF: 0,470
18. **Alkylphosphocholines as a potential pharmacologic prophylaxis for posterior capsule opacification.** Eibl KH, Liegl R, Kernt M, Priglinger S, Kampik A. *J Cataract Refract Surg*. 2009; 35:900-5. IF: 2.508

19. **Optimizing the deswelling process of organ-cultured corneas.** Wolf AH, Welge-Lüssen UC, Priglinger S, Kook D, Grueterich M, Hartmann K, Kampik A, Neubauer AS. *Cornea*. 2009; 28:524-9. IF: 1.853
20. **Anatomical and functional outcome in brilliant blue G assisted chromovitrectomy.** Henrich PB, Haritoglou C, Meyer P, Ferreira PR, Schötzau A, Katamay R, Josifova T, Schneider U, Flammer J, Priglinger S. *Acta Ophthalmol*. 2009 Apr 23. IF: 2.138
21. **Oxidative Stress-mediated Induction of MMP-1 and MMP-3 in human RPE cells.** Alge-Priglinger CS, Kreutzer T, Obholzer Katja, Wolf A, Mempel M, Kernt M, Kampik A, Priglinger SG. *Invest Ophthalmol Vis Sci*. 2009 Jun 10 . IF: 3,582
22. **Two-step LASIK after penetrating keratoplasty.** Kollias AN, Schaumberger MM, Kreutzer TC, Ulbig MW, Lackerbauer CA. *Clin Ophthalmol*. 2009;3:581-6. Epub 2009 Nov 2.
23. **Intracameral moxifloxacin: in vitro safety on human ocular cells.** Kernt M, Neubauer AS, Liegl RG, Lackerbauer CA, Eibl KH, Alge CS, Ulbig MW, A AK. *Cornea*. 2009 Jun;28(5):553-61. IF: 1,8
24. **Cytoprotective effects of a blue light-filtering intraocular lens on human retinal pigment epithelium by reducing phototoxic effects on vascular endothelial growth factor-alpha, Bax, and Bcl-2 expression.** Kernt M, Neubauer AS, Liegl R, Eibl KH, Alge CS, Lackerbauer CA, Ulbig MW, Kampik A. *J Cataract Refract Surg*. 2009 Feb;35(2):354-62. IF: 2,5
25. **A prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis.** Yactayo-Miranda Y, Ta CN, He L, Kreutzer TC, Nentwich MM, Kampik A, Mino de Kaspar H. *Graefes Arch Clin Exp Ophthalmol*. 2009 Jul;247(7):993-8. Epub 2009 Feb 11. IF: 1,8
26. **Experimental evaluation of aniline and methyl blue for intraocular surgery.** Haritoglou C, Priglinger S, Liegl R, May CA, Eibl K, Thaler S, Kampik A, Schuettauf F. *Retina*. 2009 Oct;29(9):1266-73. IF: 3,478
27. **Inhibition of human retinal pigment epithelial cell attachment, spreading, and migration by the human lectin galectin-1.** Alge-Priglinger CS, André S, Kreutzer TC, Deeg CA, Kampik A, Kernt M, Schöffl H, Priglinger SG, Gabius HJ. *Mol Vis*. 2009 Oct 23;15:2162-73. IF: 3,6
28. **Intravitreal bevacizumab for choroidal neovascularization secondary to inflammation.** Wolf A, Thurau S, Kook D, Hoeing A, Priglinger S, Kampik A, Haritoglou C. *Acta Ophthalmol*. 2009 Oct 27. IF: 2.138
29. **Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion.** Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R, Kunze C, Haritoglou C, Kampik A, Priglinger SG. *Br J Ophthalmol*. 2008; 92:351-5. IF: 2,859

30. **Delineation of the vitreous and posterior hyaloid using bromophenol blue.** Haritoglou C, Strauss R, Priglinger SG, Kreutzer T, Kampik A. *Retina*. 2008; 28:333-9. IF: 3,5
31. **Intrakamerale Lidocainanästhesie bei Kataraktoperationen: Effektivität und Sicherheit der Applikation während der Hydrodissektion;** E. Schmid, T. Neumayer, G. Rainer, M. Georgopoulos, B. Kremser, M. Luger, O. Findl; *Spektrum der Augenheilkunde (2008) 22/1: 26-30*
32. **Calcium-phosphate deposits on a hydrophilic acrylic intraocular lens after silicon oil tamponade.** Alsaedi R, Priglinger SG, Nachbauer J, Lackerbauer C, Kampik A, Haritoglou C. *Oman Journal of Ophthalmology*, 2008; 1: 25-27. IF: 3,478
33. **Retinal vessel analysis reproducibility in assessing cardiovascular disease.** Neubauer AS, Lüdtke M, Haritoglou C, Priglinger S, Kampik A. *Optom Vis Sci*. 2008; 85:247-54. IF: 1.579
34. **The protective effect of quercetin against oxidative stress in the human RPE in vitro.** Kook D, Wolf AH, Yu AL, Neubauer AS, Priglinger SG, Kampik A, Welge-Lüssen UC. *Invest Ophthalmol Vis Sci*. 2008; 49:1712-20. IF: 3,582
35. **Capsular tension ring-based in vitro capsule opacification model.** Burger J, Kreutzer T, Alge CS, Strauss RW, Eibl K, Haritoglou C, Neubauer AS, Kampik A, Priglinger SG. *J Cataract Refract Surg*. 2008; 34:1167-72. IF: 2,508
36. **An in vivo evaluation of Brilliant Blue G in animals and humans.** Remy M, Thaler S, Schumann RG, May CA, Fiedorowicz M, Schuettauf F, Grüterich M, Priglinger SG, Nentwich MM, Kampik A, Haritoglou C. *Br J Ophthalmol*. 2008; 92:1142-7. IF: 2.859
37. **Nonmydriatic screening for diabetic retinopathy by ultra-widefield scanning laser ophthalmoscopy (Optomap).** Neubauer AS, Kernt M, Haritoglou C, Priglinger SG, Kampik A, Ulbig MW. *Graefes Arch Clin Exp Ophthalmol*. 2008; 246:229-35. IF: 1,498
38. **Idiopathic macular holes: ultrastructural aspects of surgical failure.** Schumann RG, Rohleder M, Schaumberger MM, Haritoglou C, Kampik A, Gandorfer A. *Retina*. 2008 Feb;28(2):340-9.
39. **Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.** Kook D, Wolf A, Kreutzer T, Neubauer A, Strauss R, Ulbig M, Kampik A, Haritoglou C. *Retina*. 2008 Oct;28(8):1053-60.
40. **A prospective randomized study to determine the efficacy of preoperative topical levofloxacin in reducing conjunctival bacterial flora.** Miño de Kaspar H, Kreutzer TC, Aguirre-Romo I, Ta CN, Dudichum J, Bayrhof M, Klauss V, Kampik A. *Am J Ophthalmol*. 2008 Jan;145(1):136-142. Epub 2007 Nov 8.
41. **Staining and peeling of the internal limiting membrane using a fluorescent dye (Rhodamine 6 G).** Haritoglou C, Kreutzer T, Tadayoni R, Langhals H, May CA, Thaler S, Kampik A. *Br J Ophthalmol*. 2008 Sep;92(9):1265-8. Epub 2008 Jun 27.

42. **Anti-VEGF treatment for retinal angiomatous proliferation.** Wolf A, Kook D, Kreutzer T, Gandorfer A, Haritoglou C, Kampik A, Ulbig M. *Ophthalmologe*. 2008 Sep;105(9):845-51. German.
43. **Retinal pigment epithelial tears after intravitreal injection of bevacizumab for AMD: Frequency and progress.** Kook D, Wolf A, Neubauer AS, Haritoglou C, Priglinger SG, Kampik A, Ulbig MW. *Ophthalmologe*. 2008;105:158-64.

2007

44. **Visual quality of life after Macular Hole Surgery: Outcome and predictive factors.** Hirneiss C, Neubauer AS, Gass CA, Reiniger IW, Priglinger SG, Kampik A, Haritoglou C. *Br J Ophthalmol*. 2007;91:481-4.
45. **Topography of Diabetic Macular Edema compared to Fluorescein Angiography.** Neubauer AS, Chryssafis C, Priglinger SG, Haritoglou C, Thiel M, Welge-Lüssen U, Kampik A, Ulbig M. *Acta Ophthalmol Scand*. 2007;85:32-9. IF: 2,138. IF: 2,859
46. **Hypoxia/Reoxygenation and TGF-beta Increase alphaB-Crystallin Expression in Human Optic Nerve Head Astrocytes.** Yu AL, Fuchshofer R, Birke M, Priglinger SG, Eibl KH, Kampik A, Bloemendal H, Welge-Lussen U. *Exp Eye Res*. 2007;84:694-706. IF: 2,579
47. **Long-term functional outcome of macular hole surgery correlated to Optical Coherence Tomography (OCT) measurements.** Haritoglou C, Neubauer A, Reiniger IW, Priglinger SG, Gass CA, Kampik A. *Clin Experiment Ophthalmol*. 2007;35:208-13. IF: 1,347
48. **Pulsed Electron Avalanche Knife (PEAK-fc): New Technology for Cataract Surgery.** Priglinger SG, Palanker D, Alge CS, Haritoglou H, Grueterich M, Kampik A. *Br J Ophthalmol*. 2007; 91:949-54. IF: 2,859
49. **Vitreoretinal surgery using Bromphenol blue as a vital stain: Evaluation of staining characteristics in humans.** Haritoglou C, Schumann R, Strauss R, Priglinger S, Neubauer AS, Kampik A. *Br J Ophthalmol*. 2007; 91:1125-8. IF: 2,859
50. **Eccentric lamellar keratolimbal grafts harvested with a manually guided microkeratome. Technical report.** Grueterich M, Kenyon KR, Priglinger S, Welge-Luessen U, Lackerbauer C, Kampik A. *Ophthalmic Res*. 2007; 39:179-83. IF: 1,317
51. **Intravitreal Bevacizumab for Central Retinal Vein Occlusion - Six Month Results of a Prospective Trial.** Priglinger SG, Wolf AH, Kreutzer TC, Kook D, Hofer A, Strauss RW, Alge CS, Kunze C, Haritoglou C, Kampik A. *Retina*. 2007; 27:1004-12. IF: 3,478
52. **Indications and Clinical Outcome of Capsular Tension Ring (CTR) Implantation: A Review of 9528 Cataract Surgeries.** Tribus C, Alge CS, Haritoglou C, Kampik A, Mueller A, Priglinger SG. *Clinical Ophthalmology*. 2007;1(1) 65-69. IF: 1,347

53. **Image quality characteristics of a novel colour scanning digital ophthalmoscope (SDO) compared with fundus photography.** Strauss RW, Krieglstein TR, Priglinger SG, Reis W, Ulbig MW, Kampik A, Neubauer AS. *Ophthalmic Physiol Opt.* 2007; 27:611-8. IF: 1,00
54. **Bevacizumab and retinal ischemia.** Neubauer AS, Kook D, Haritoglou C, Priglinger SG, Kampik A, Ulbig MW, Ceklic L. *Ophthalmology.* 2007; 114:2096. IF: 5,296
55. **Bromphenol blue staining in eyes with mature cataract.** Haritoglou C, Priglinger SG, Strauss R, Gandorfer A, Kampik A. *J Cataract Refract Surg.* 2007; 33:2155-7. IF: 2,508
56. **Light absorbing properties of indocyanine green (ICG) in solution and on the retinal surface – an ex vivo approach.** Haritoglou C, Freyer W, Priglinger SG, Kampik A. *Graefes Arch Clin Exp Ophthalmol.* 2006; 244:1196-202. IF: 1,77

2006

57. **Galectin-1 influences migration of retinal pigment epithelial cells.** *Alge CS, *Priglinger SG, Kook D, Haritoglou C, Welge-Luessen U, Kampik A. *Invest Ophthalmol Vis Sci.* 2006; 47:415-426. (*contributed equally). IF: 3,582
58. **Inhibition of Human Retinal Pigment Epithelial Cell Attachment, Spreading and Migration by Alkylphosphocholines through Microfilament Modification.** Eibl KH, Kook D, Priglinger S, Haritoglou C, Kampik A, Welge-Luessen U. *Invest Ophthalmol Vis Sci.* 2006; 47:364-370. IF: 3,582
59. **Ultrastructure of the vitreomacular interface in full-thickness idiopathic macular holes: a consecutive analysis of 100 cases.** Schumann RG, Schaumberger MM, Rohleder M, Haritoglou C, Kampik A, Gandorfer A. *Am J Ophthalmol.* 2006 Jun;141(6):1112-1119.
60. **Evaluation of the internal limiting membrane after conventional peeling during macular hole surgery.** Haritoglou C, Schumann R, Reiniger I, Rohleder M, Priglinger SG, Kampik A, Gandorfer A. *Retina* 2006; 26:21-24. IF: 3,478
61. **Immunohistochemical findings after LASIK confirm in vitro LASIK model.** Priglinger SG, May CA, Alge CS, Wolf A, Neubauer AS, Haritoglou C, Kampik A, Welge-Lüßen U. *Cornea.* 2006; 25:331-335. IF: 1,853
62. **Differential protein profiling of primary versus immortalized human RPE cells identifies expression patterns associated with cell-matrix interactions and cell survival.** Alge CS, Hauck SM, Priglinger SG, Kampik A, Ueffing M. *J Proteome Res.* 2006; 5:862-878. IF: 6,9
63. **Klinische Aspekte bei Frühgeborenen-Retinopathie (ROP). Ergebnisse nach Dioden-Laserkoagulation.** Rudolph G, Buhl M, Pietschmann M, Priglinger S, Boergen K-P, Kampik A. *Klin Monatsbl Augenheilkd.* 2006; 223:528-533. IF: 0,470

64. **Five year follow-up of macular hole surgery with peeling of the internal limiting membrane (ILM): Update of a prospective study.** Haritoglou C, Reiniger I, Schaumberger M, Gass C, Priglinger SG, Kampik A. *Retina* 2006; 26:618-622. IF: 3,478
65. **Tissue Transglutaminase modifies Extracellular Matrix after Glaucoma Filtering Surgery** Priglinger SG, Alge CS, Kook D, Thiel M, Schumann R, Kampik A, Welge-Luessen U. *Invest Ophthalmol Vis Sci.* 2006;47:3835-45. IF: 3,58
66. **Pulsed Electron Avalanche Knife (PEAK-fc): New Technology for capsulotomy in congenital and mature cataract.** Priglinger SG, Haritoglou C, Palanker D, Kook D, Grueterich M, Mueller A, Alge CS, Kampik A. *J Cataract Refract Surg.* 2006;32:1085-1088. IF: 2,508
67. **Short time in vivo evaluation of novel vital dyes for intraocular surgery.** Haritoglou C, Tadayoni R, May CA, Gass C, Freyer W, Priglinger SG, Kampik A. *Retina* 2006; 26:673-678. IF: 3,478
68. **Keratinocyte transglutaminase in proliferative vitreoretinopathy.** Priglinger SG, Alge CS, Kreutzer TC, Neubauer AS, Haritoglou C, Kampik A, Welge-Luessen U. *Invest Ophthalmol Vis Sci.* 2006; 47:4990-4997. IF: 3,582
69. **Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.** Haritoglou C, Kook D, Neubauer AS, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A. *Retina.* 2006; 26:999-1005. IF: 3,478

2005

70. **Histology of the vitreoretinal interface after indocyanine green staining of the ILM with illumination using a halogen and xenon light source.** Haritoglou C, Priglinger SG, Gandorfer A, Welge-Luessen U, Kampik A. *Invest Ophthalmol Vis Sci* 2005; 46: 1468-72. IF: 3,582
71. **Staining and peeling of the internal limiting membrane in the cat eye.** Gandorfer A, Rohleder M, Charteris DG, Sethi C, Kampik A, Luthert P. *Curr Eye Res.* 2005 Nov;30(11):977-87.
72. **Use of rapid antibiotic susceptibility testing in bacterial endophthalmitis.** de Kaspar HM, Kreutzer TC, Ta CN, Kampik A. *Retina.* 2005 Apr-May;25(3):386-7; author reply 387-8.
73. **Epiretinal pathology of diffuse diabetic macular edema associated with vitreomacular traction.** Gandorfer A, Rohleder M, Grosselfinger S, Haritoglou C, Ulbig M, Kampik A. *Am J Ophthalmol.* 2005 Apr;139(4):638-52.
74. **Ultrastructure of vitreomacular traction syndrome associated with persistent hyaloid artery.** Gandorfer A, Rohleder M, Charteris D, Kampik A, Luthert P. *Eye (Lond).* 2005 Mar;19(3):333-6.

75. **Pulsed Electron Avalanche Knife (PEAK-fc) in vitreoretinal surgery:** Priglinger SG, Haritoglou C, Mueller A, Grueterich M, Strauss RW, Alge CS, Gandorfer A, Palanker D, Kampik A. *Retina*. 2005;25:889-896. IF: 3,478
76. **Pulsed Electron Avalanche Knife (PEAK-fc®) for Dissection of Retinal Tissue.** Priglinger SG, Haritoglou C, Palanker DV, Alge CS, Gandorfer A, Kampik A. *Arch Ophthalmol*. 2005 Oct;123(10):1412-8. IF: 3,242
77. **An evaluation of novel dyes for intraocular surgery.** Haritoglou C, Yu A, Freyer W, Priglinger SG, May CA, Alge C, Eibl K, Welge-Luessen U, Kampik A. *Invest Ophthalmol Vis Sci*. 2005;46:3315-3322. IF: 3,582
78. **Absence of scar formation in a human donor cornea with prior laser in situ keratomileusis (LASIK).** Priglinger SG, May CA, Alge CS, Wolf A, Neubauer AS, Kampik A, Welge-Lüßen U. *J Cataract Refract Surg*. 2005;31:1403-1408. IF: 2,508
79. **Mapping of retinal pigment epithelium in exudative age related macular degeneration.** Neubauer AS, Thiel M, Priglinger S, Chryssafis C, Alge C, Welge-Lüßem U, Kampik A. *Graefes Arch Clin Exp Ophthalmol*. 2005;18:1-10; IF: 1,77
80. **Screening der diabetischen Retinopathie und Papillentopographie mit dem "Retinal Thickness Analyzer" (RTA)** Neubauer AS, Chryssafis C, Thiel M, Priglinger S, Welge-Lussen U, Kampik A. *Ophthalmologe*. 2005;102:251-8. IF: 1,133

2004

81. **Laser in situ keratomileusis in human corneas; New organ culture model.** May* CA, Priglinger* SG, Neubauer AS, Alge CS, Ludwig K, Kampik A, Welge-Lüßen U. *J Cataract Refract Surg*. 2004 Jan;30(1):186-93. (* contributed equally). IF: 2,508
82. **Posterior vitreous detachment induced by microplasmin.** Gandorfer A, Rohleder M, Sethi C, Eckle D, Welge-Lüssen U, Kampik A, Luthert P, Charteris D. *Invest Ophthalmol Vis Sci*. 2004 Feb;45(2):641-7.
83. **TGF-beta2-Induced Cell Surface Tissue Transglutaminase Increases Adhesion and Migration of RPE Cells on Fibronectin through the Gelatin-Binding Domain.** Priglinger SG, Alge CS, Neubauer AS, Kristin N, Hirneiss C, Eibl K, Kampik A, Welge-Lussen U. *Invest Ophthalmol Vis Sci*. 2004 Mar;45(3):955-63. IF: 3,582
84. **Alkylphosphocholines: A New Therapeutic Option in Glaucoma Filtration Surgery.** Eibl KH, Banas B, Kook D, Ohlmann A, Priglinger S, Kampik A, Welge-Luessen U. *Invest Ophthalmol Vis Sci*. 2004; 45:2619-24. IF: 3,582
85. **Functional outcome after trypan-blue-assisted vitrectomy for macular pucker: a prospective, randomized, comparative trial.** Haritoglou C, Eibl K, Schaumberger M, Müller AJ, Priglinger S, Alge C, Kampik A. *Am J Ophthalmol* 2004; 138: 1-5. IF: 3,102

86. **Trypan blue in macular pucker surgery: an evaluation of histology and functional outcome.** Haritoglou C, Gandorfer A, Schaumberger M, Priglinger SG, Mueller AJ, Gass CA, Anselm Kampik A. *Retina* 2004; 24: 582-590 IF: 3,478

2003

87. **Transglutaminase as a Modifying Enzyme of the Extracellular Matrix in PVR Membranes Tissue.** Priglinger SG, May CA, Neubauer AS, Alge CS, Schoenfeld CL, Kampik A, Welge-Lussen U. *Invest Ophthalmol Vis Sci.* 2003 Jan;44(1):355-64. IF: 3,582
88. **Optical coherence tomography for the detection of laser in situ keratomileusis in donor corneas.** Priglinger SG, Neubauer AS, May CA, Alge CS, Wolf AH, Mueller A, Ludwig K, Kampik A, Welge-Luessen U. *Cornea.* 2003 Jan;22(1):46-50. IF: 1,853
89. **Alkylphosphocholines inhibit proliferation of human retinal pigment epithelial cells.** Eibl KH, Banas B, Schoenfeld CL, May CA, Neubauer AS, Priglinger S, Kampik A, Welge-Lussen U. *Invest Ophthalmol Vis Sci.* 2003 Aug;44(8):3556-61. IF: 3,582
90. **Comparative proteome analysis of native differentiated and cultured dedifferentiated human RPE cells.** Alge CS, Suppmann S, Priglinger SG, Neubauer AS, May CA, Hauck S, Welge-Lussen U, Ueffing M, Kampik A. *Invest Ophthalmol Vis Sci.* 2003 Aug;44(8):3629-41. IF: 3,582
91. **Tele-screening for diabetic retinopathy with the retinal thickness analyzer.** Neubauer AS, Welge-Lussen UC, Thiel MJ, Alge C, Priglinger SG, Hirneiss C, Ulbig MW, Kampik A. *Diabetes Care.* 2003 Oct;26(10):2890-7. IF: 7,851

2002

92. **Vitreoretinal morphology of plasmin-treated human eyes.** Gandorfer A, Priglinger S, Schebitz K, Hoops J, Ulbig M, Ruckhofer J, Grabner G, Kampik A. *Am J Ophthalmol.* 2002;133:156-9. IF: 3,102
93. **Epiretinal pathology of vitreomacular traction syndrome.** Gandorfer A, Rohleder M, Kampik A. *Br J Ophthalmol.* 2002 Aug;86(8):902-9.
94. **Sterile Structural Imaging of Donor Cornea by Optical Coherence Tomography.** Neubauer AS, Priglinger SG, Thiel MJ, May CA, Welge-Lüßen UC. *Cornea.* 2002 Jul;21(5):490-494. IF: 1,853
95. **Consenting to cornea donation: influencing factors.** Krieglstein TR, Welge-Lussen UC, Priglinger S, Kampik A, Priemer F, Neubauer AS. *Graefes Arch Clin Exp Ophthalmol.* 2002 Oct; 240(10):816-821. IF: 1,77
96. **Retinal Pigment Epithelium Is Protected Against Apoptosis by alphaB-Crystallin.** Alge CS, Priglinger SG, Neubauer AS, Kampik A, Zillig M, Bloemendal H, Welge-Lussen U. *Invest Ophthalmol Vis Sci.* 2002 Nov;43(11):3575-82. IF: 3,582

2001

97. **PUVA downregulates whn expression in primary mouse keratinocytes.** Alge C, Baxter RM, Doyle ME, Moor AC, Brissette JL, Ortel B. *J Photochem Photobiol B.* 2001 Nov 1;64(1):75-81.
98. **Hornhautspende: Einflussfaktoren der Einwilligung.** Krieglstein TR, Neubauer AS, Welge-Lüssen U, Priglinger S, Kampik A, Priemer F. *Ophthalmologe* 2001 Jun;98(6):545-9. IF: 1,133
99. **Elektronische oder papiergebundene Patientenakte -ein Kosten-Nutzenvergleich.** Neubauer AS, Priglinger S, Ehrt O. *Ophthalmologe* 2001 Nov;98(11): 1083-1088. IF: 1,133
100. **Comparison of foveal thickness measured with the retinal thickness analyzer and optical coherence tomography.** Neubauer AS, Priglinger S, Ullrich S, Bechmann M, Thiel MJ, Ulbig MW, Kampik A. *Retina.* 2001;21(6): 596-601. IF: 3,478

1998

101. **Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia.** Gaiger A, Schmid D, Heinze G, Linnerth B, Greinix H, Kalhs P, Tisljar K, Priglinger S, Laczika K, Mitterbauer M, Novak M, Mitterbauer G, Mannhalter C, Haas OA, Lechner K, Jager U. *Leukemia.* 1998; 12:1886-94. IF: 8,634